{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:58:19Z","timestamp":1794851899178,"version":"4.9.1"},"reference-count":104,"publisher":"American Society of Hematology","issue":"16","license":[{"start":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T00:00:00Z","timestamp":1718064000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,8,27]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Multiple chimeric antigen receptor (CAR) T-cell therapies are US Food and Drug Administration\u2013approved, and several are under development. Although effective for some cancers, toxicities remain a limitation. The most common toxicities, that is, cytokine release syndrome and immune effector cell\u2013associated neurotoxicity syndrome, are well described. With increasing utilization, providers worldwide are reporting other emergent and often complicated toxicities. Given the evolving toxicity profiles and urgent need to catalog these emerging and emergent CAR T-cell toxicities and describe management approaches, the American Society of Hematology Subcommittee on Emerging Gene and Cell Therapies organized the first scientific workshop on CAR T-cell toxicities during the annual society meeting. The workshop functioned to (1) aggregate reports of CAR T-cell emergent toxicities, including movement disorders after B-cell maturation antigen CAR T cell, coagulation abnormalities, and prolonged cytopenia; (2) disseminate bedside-to-bench efforts elucidating pathophysiological mechanisms of CAR T-cell toxicities, including the intestinal microbiota and systemic immune dysregulation; and (3) highlight gaps in the availability of clinical tests, such as cytokine measurements, which could be used to expand our knowledge around the monitoring of toxicities. Key themes emerged. First, although clinical manifestations may develop before the pathophysiologic mechanisms are understood, they must be studied to aid in the detection and prevention of such toxicities. Second, systemic immune dysregulation appears to be central to these emergent toxicities, and research is needed to elucidate the links between tumors, CAR T cells, and microbiota. Finally, there was a consensus around the urgency to create a repository to capture emergent CAR T-cell toxicities and the real-world management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024013044","type":"journal-article","created":{"date-parts":[[2024,6,11]],"date-time":"2024-06-11T13:02:40Z","timestamp":1718110960000},"page":"4348-4358","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":40,"title":["CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3744-8672","authenticated-orcid":false,"given":"Fabiana","family":"Perna","sequence":"first","affiliation":[{"name":"1Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir","family":"Parekh","sequence":"additional","affiliation":[{"name":"2Division of Hematology and Medical Oncology, The Tish Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8005-3836","authenticated-orcid":false,"given":"Caroline","family":"Diorio","sequence":"additional","affiliation":[{"name":"3Department of Pediatrics, Children\u2019s Hospital of Philadelphia, University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2702-0381","authenticated-orcid":false,"given":"Melody","family":"Smith","sequence":"additional","affiliation":[{"name":"4Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3905-0251","authenticated-orcid":false,"given":"Marion","family":"Subklewe","sequence":"additional","affiliation":[{"name":"5Department of Medicine III, University Hospital, Ludwig-Maximilians-Universit\u00e4t M\u00fcnchen, Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Mehta","sequence":"additional","affiliation":[{"name":"6Department of Medicine, Indiana University School of Medicine, Indianapolis, IN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick L.","family":"Locke","sequence":"additional","affiliation":[{"name":"1Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"7Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,8,16]]},"reference":[{"issue":"4","key":"2024082712403397400_bib1","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2024082712403397400_bib2","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy - assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"2024082712403397400_bib3","article-title":"Society for immunotherapy of cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8(2):e001511","author":"Maus","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"20","key":"2024082712403397400_bib4","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1182\/blood-2018-12-893396","article-title":"Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells","volume":"133","author":"Karschnia","year":"2019","journal-title":"Blood"},{"issue":"27","key":"2024082712403397400_bib5","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"27","key":"2024082712403397400_bib6","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024082712403397400_bib7","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41591-019-0737-3","article-title":"Safety and feasibility of anti-CD19 CAR T cells with fully human binding domains in patients with B-cell lymphoma","volume":"26","author":"Brudno","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"2024082712403397400_bib8","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1158\/2326-6066.CIR-21-0269","article-title":"Engineered T-cell receptor T cells for cancer immunotherapy","volume":"9","author":"Greenbaum","year":"2021","journal-title":"Cancer Immunol Res"},{"issue":"17","key":"2024082712403397400_bib9","doi-asserted-by":"crossref","first-page":"3397","DOI":"10.1182\/bloodadvances.2020003885","article-title":"Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells","volume":"5","author":"Pennisi","year":"2021","journal-title":"Blood Adv"},{"issue":"12","key":"2024082712403397400_bib10","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov"},{"issue":"10254","key":"2024082712403397400_bib11","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"2024082712403397400_bib12","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1016\/j.ymthe.2017.07.004","article-title":"Long-duration complete remissions of diffuse large B cell lymphoma after anti-CD19 chimeric antigen receptor T cell therapy","volume":"25","author":"Kochenderfer","year":"2017","journal-title":"Mol Ther"},{"issue":"16","key":"2024082712403397400_bib13","doi-asserted-by":"crossref","first-page":"1803","DOI":"10.1200\/JCO.2016.71.3024","article-title":"Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 levels","volume":"35","author":"Kochenderfer","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"2024082712403397400_bib14","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8(8)","author":"Santomasso","year":"2018","journal-title":"Cancer Discov"},{"issue":"12","key":"2024082712403397400_bib15","doi-asserted-by":"crossref","first-page":"1536","DOI":"10.1001\/jamaneurol.2020.2703","article-title":"Clinical predictors of neurotoxicity after chimeric antigen receptor T-cell therapy","volume":"77","author":"Rubin","year":"2020","journal-title":"JAMA Neurol"},{"issue":"4","key":"2024082712403397400_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"35","key":"2024082712403397400_bib17","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of immune-related adverse events in patients treated with chimeric antigen receptor T-cell therapy: ASCO guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"26","key":"2024082712403397400_bib18","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.1182\/blood-2016-04-703751","article-title":"Toxicities of chimeric antigen receptor T cells: recognition and management","volume":"127","author":"Brudno","year":"2016","journal-title":"Blood"},{"issue":"13","key":"2024082712403397400_bib19","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1056\/NEJMoa2209900","article-title":"GPRC5D-targeted CAR T cells for myeloma","volume":"387","author":"Mailankody","year":"2022","journal-title":"N\u00a0Engl J Med"},{"issue":"7903","key":"2024082712403397400_bib20","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","article-title":"GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas","volume":"603","author":"Majzner","year":"2022","journal-title":"Nature"},{"issue":"12","key":"2024082712403397400_bib21","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Van Oekelen","year":"2021","journal-title":"Nat Med"},{"issue":"2","key":"2024082712403397400_bib22","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.ymthe.2021.01.011","article-title":"Safety starts with selecting the targets","volume":"29","author":"Perna","year":"2021","journal-title":"Mol Ther"},{"issue":"13","key":"2024082712403397400_bib23","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1200\/JCO.2006.05.9964","article-title":"Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience","volume":"24","author":"Lamers","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"2024082712403397400_bib24","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ccell.2017.09.004","article-title":"Integrating proteomics and transcriptomics for systematic combinatorial chimeric antigen receptor therapy of AML","volume":"32","author":"Perna","year":"2017","journal-title":"Cancer Cell"},{"issue":"7","key":"2024082712403397400_bib25","doi-asserted-by":"crossref","first-page":"101110","DOI":"10.1016\/j.xcrm.2023.101110","article-title":"A\u00a0target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma","volume":"4","author":"Di Meo","year":"2023","journal-title":"Cell Rep Med"},{"issue":"6","key":"2024082712403397400_bib26","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1158\/1078-0432.CCR-17-0432","article-title":"Phase I study of chimeric antigen receptor-modified T cells in patients with EGFR-positive advanced biliary tract cancers","volume":"24","author":"Guo","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2024082712403397400_bib27","first-page":"2443","article-title":"How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity","volume":"141","author":"Santomasso","year":"2023","journal-title":"Blood"},{"issue":"3","key":"2024082712403397400_bib28","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/mt.2010.272","article-title":"T\u00a0cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis","volume":"19","author":"Parkhurst","year":"2011","journal-title":"Mol Ther"},{"issue":"4","key":"2024082712403397400_bib29","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/mt.2013.17","article-title":"Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity","volume":"21","author":"Lamers","year":"2013","journal-title":"Mol Ther"},{"issue":"4","key":"2024082712403397400_bib30","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol Ther"},{"issue":"2","key":"2024082712403397400_bib31","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-022-00629-1","article-title":"Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies","volume":"12","author":"Cohen","year":"2022","journal-title":"Blood Cancer J"},{"issue":"14","key":"2024082712403397400_bib32","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1182\/blood.2023021429","article-title":"Chemotherapy-induced reversal of ciltacabtagene autoleucel-associated movement and neurocognitive toxicity","volume":"142","author":"Graham","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024082712403397400_bib33","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"issue":"16","key":"2024082712403397400_bib34","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood.2021015161","article-title":"Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma","volume":"139","author":"Anderson","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024082712403397400_bib35","doi-asserted-by":"crossref","first-page":"4121","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat Commun"},{"issue":"11","key":"2024082712403397400_bib36","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1016\/j.ccell.2023.09.010","article-title":"Cooperative CAR targeting to selectively eliminate AML and minimize escape","volume":"41","author":"Haubner","year":"2023","journal-title":"Cancer Cell"},{"issue":"7952","key":"2024082712403397400_bib37","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"1","key":"2024082712403397400_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nbt.2459","article-title":"Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells","volume":"31","author":"Kloss","year":"2013","journal-title":"Nat Biotechnol"},{"issue":"16","key":"2024082712403397400_bib39","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"2024082712403397400_bib40","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"6(6)","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"5","key":"2024082712403397400_bib41","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1200\/JCO.20.01616","article-title":"How I manage: pathophysiology and management of toxicity of chimeric antigen receptor T-cell therapies","volume":"39","author":"Reagan","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"2024082712403397400_bib42","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jtct.2023.10.012","article-title":"INSPIRED symposium part 4B: CAR T cell correlative studies-established findings and future priorities","volume":"30","author":"Ligon","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"7906","key":"2024082712403397400_bib43","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022","journal-title":"Nature"},{"issue":"19","key":"2024082712403397400_bib44","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"18","key":"2024082712403397400_bib45","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"2024082712403397400_bib46","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2024082712403397400_bib47","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"11","key":"2024082712403397400_bib48","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"},{"issue":"7","key":"2024082712403397400_bib49","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"17","key":"2024082712403397400_bib50","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell associated neurotoxicity syndrome in B-cell ALL patients receiving CART19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"20","key":"2024082712403397400_bib51","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/bloodadvances.2023010708","article-title":"Free interleukin-18 is elevated in CD22 CAR T-cell associated hemophagocytic lymphohistiocytosis-like toxicities","volume":"7","author":"Rocco","year":"2023","journal-title":"Blood Adv"},{"key":"2024082712403397400_bib52","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2024.03.030","article-title":"Need for standardization of cytokine profiling in CAR T cell therapy","author":"Biery","year":"26  2024","journal-title":"Mol Ther"},{"issue":"1","key":"2024082712403397400_bib53","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"5","key":"2024082712403397400_bib54","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.bbmt.2020.01.021","article-title":"Unexpected toxicities when nivolumab was given as maintenance therapy following allogeneic stem cell transplantation","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"18","key":"2024082712403397400_bib55","doi-asserted-by":"crossref","first-page":"975","DOI":"10.21037\/atm-22-3814","article-title":"The correlation factors and prognostic significance of coagulation disorders after chimeric antigen receptor T cell therapy in hematological malignancies: a cohort study","volume":"10","author":"Dong","year":"2022","journal-title":"Ann Transl Med"},{"issue":"14","key":"2024082712403397400_bib56","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1182\/bloodadvances.2022007454","article-title":"Relative hypercoagulation induced by suppressed fibrinolysis after tisagenlecleucel infusion in malignant lymphoma","volume":"6","author":"Yamasaki-Morita","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2024082712403397400_bib57","doi-asserted-by":"crossref","first-page":"4086","DOI":"10.1182\/bloodadvances.2020002060","article-title":"Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma","volume":"4","author":"Hashmi","year":"2020","journal-title":"Blood Adv"},{"issue":"21","key":"2024082712403397400_bib58","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1182\/bloodadvances.2021004716","article-title":"Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy","volume":"5","author":"Johnsrud","year":"2021","journal-title":"Blood Adv"},{"key":"2024082712403397400_bib59","article-title":"Thrombotic events are unusual toxicities of chimeric antigen receptor T-cell therapies","volume":"24(9):8349","author":"Schorr","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"2024082712403397400_bib60","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.bbmt.2019.11.027","article-title":"Coagulation disorders after chimeric antigen receptor T cell therapy: analysis of 100 Patients with relapsed and refractory hematologic malignancies","volume":"26","author":"Wang","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"13","key":"2024082712403397400_bib61","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/bloodadvances.2020001972","article-title":"DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality","volume":"4","author":"Wudhikarn","year":"2020","journal-title":"Blood Adv"},{"issue":"5","key":"2024082712403397400_bib62","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024082712403397400_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"2024082712403397400_bib64","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"10","key":"2024082712403397400_bib65","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/S1470-2045(21)00375-2","article-title":"Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Schuster","year":"2021","journal-title":"Lancet Oncol"},{"issue":"24","key":"2024082712403397400_bib66","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"5","key":"2024082712403397400_bib67","doi-asserted-by":"crossref","first-page":"e004475","DOI":"10.1136\/jitc-2021-004475","article-title":"The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R\/R LBCL","volume":"10","author":"Rejeski","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"issue":"7","key":"2024082712403397400_bib68","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv"},{"issue":"38","key":"2024082712403397400_bib69","doi-asserted-by":"crossref","first-page":"eadg3919","DOI":"10.1126\/sciadv.adg3919","article-title":"Severe hematotoxicity after CD19 CAR-T therapy is associated with suppressive immune dysregulation and limited CAR-T expansion","volume":"9","author":"Rejeski","year":"2023","journal-title":"Sci Adv"},{"issue":"10","key":"2024082712403397400_bib70","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1038\/s41408-022-00741-2","article-title":"Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma","volume":"12","author":"Miller","year":"2022","journal-title":"Blood Cancer J"},{"issue":"3","key":"2024082712403397400_bib71","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/s41409-021-01526-0","article-title":"Effect of early granulocyte-colony-stimulating factor administration in the prevention of febrile neutropenia and impact on toxicity and efficacy of anti-CD19 CAR-T in patients with relapsed\/refractory B-cell lymphoma","volume":"57","author":"Lievin","year":"2022","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"2024082712403397400_bib72","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"4","key":"2024082712403397400_bib73","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1182\/bloodadvances.2022008066","article-title":"Prolonged thrombocytopenia after CAR T-cell therapy: the role of thrombopoietin receptor agonists","volume":"7","author":"Drillet","year":"2023","journal-title":"Blood Adv"},{"issue":"16","key":"2024082712403397400_bib74","doi-asserted-by":"crossref","first-page":"4719","DOI":"10.1182\/bloodadvances.2022007776","article-title":"Safety and feasibility of stem cell boost as a salvage therapy for severe hematotoxicity after CD19 CAR T-cell therapy","volume":"6","author":"Rejeski","year":"2022","journal-title":"Blood Adv"},{"issue":"16","key":"2024082712403397400_bib75","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1182\/bloodadvances.2022007572","article-title":"CD34+-selected stem cell boost can safely improve cytopenias following CAR T-cell therapy","volume":"6","author":"Mullanfiroze","year":"2022","journal-title":"Blood Adv"},{"issue":"4","key":"2024082712403397400_bib76","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/bloodadvances.2021006827","article-title":"Reduced intensity hematopoietic stem cell transplantation for accelerated-phase myelofibrosis","volume":"6","author":"Gagelmann","year":"2022","journal-title":"Blood Adv"},{"issue":"1","key":"2024082712403397400_bib77","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/s13045-023-01465-x","article-title":"The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed\/refractory multiple myeloma","volume":"16","author":"Rejeski","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"issue":"11","key":"2024082712403397400_bib78","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1038\/s41591-022-02069-7","article-title":"Author correction: gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"29","author":"Smith","year":"2023","journal-title":"Nat Med"},{"issue":"4","key":"2024082712403397400_bib79","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1038\/s41591-022-01702-9","article-title":"Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy","volume":"28","author":"Smith","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"2024082712403397400_bib80","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1038\/s41591-023-02234-6","article-title":"A\u00a0non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy","volume":"29","author":"Stein-Thoeringer","year":"2023","journal-title":"Nat Med"},{"issue":"1","key":"2024082712403397400_bib81","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1038\/s41467-022-32960-3","article-title":"CAR-T cell therapy-related cytokine release syndrome and therapeutic response is modulated by the gut microbiome in hematologic malignancies","volume":"13","author":"Hu","year":"2022","journal-title":"Nat Commun"},{"issue":"24","key":"2024082712403397400_bib82","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"issue":"7","key":"2024082712403397400_bib83","doi-asserted-by":"crossref","first-page":"438.e1","DOI":"10.1016\/j.jtct.2023.03.006","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"2","key":"2024082712403397400_bib84","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","article-title":"Unanswered questions following reports of secondary malignancies after CAR-T cell therapy","volume":"30","author":"Levine","year":"2024","journal-title":"Nat Med"},{"issue":"4","key":"2024082712403397400_bib85","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br J Haematol"},{"issue":"13","key":"2024082712403397400_bib86","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"8","key":"2024082712403397400_bib87","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncol"},{"issue":"18","key":"2024082712403397400_bib88","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"issue":"19","key":"2024082712403397400_bib89","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood.2019002936","article-title":"Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure","volume":"135","author":"Gauthier","year":"2020","journal-title":"Blood"},{"issue":"19","key":"2024082712403397400_bib90","doi-asserted-by":"crossref","first-page":"e25786","DOI":"10.1097\/MD.0000000000025786","article-title":"Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: a case report","volume":"100","author":"Zi","year":"2021","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"2024082712403397400_bib91","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J\u00a0Cell Mol Med"},{"issue":"23","key":"2024082712403397400_bib92","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2024082712403397400_bib93","doi-asserted-by":"crossref","first-page":"e001114","DOI":"10.1136\/jitc-2020-001114","article-title":"Management of a patient with mantle cell lymphoma who developed severe neurotoxicity after chimeric antigen receptor T-cell therapy in ZUMA-2","volume":"8","author":"Wang","year":"2020","journal-title":"J\u00a0Immunother Cancer"},{"issue":"23","key":"2024082712403397400_bib94","doi-asserted-by":"crossref","first-page":"3306","DOI":"10.1182\/blood.2021010784","article-title":"Utility of a safety switch to abrogate CD19.CAR T-cell-associated neurotoxicity","volume":"137","author":"Foster","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082712403397400_bib95","doi-asserted-by":"crossref","first-page":"7493","DOI":"10.1182\/blood-2022-157448","article-title":"Primary analysis of a pilot study of prophylactic anakinra to mitigate CAR T cell-associated toxicity in patients with relapsed or refractory large B-cell lymphoma","volume":"140","author":"Strati","year":"2022","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082712403397400_bib96","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1182\/blood-2021-150431","article-title":"A\u00a0phase II study of prophylactic anakinra to prevent CRS and neurotoxicity in patients receiving CD19 CAR T cell therapy for relapsed or refractory lymphoma","volume":"138","author":"Park","year":"2021","journal-title":"Blood"},{"issue":"suppl 1","key":"2024082712403397400_bib97","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtageneciloleucel (axi-cel; KTE-C19) treatment for patients with refractory,aggressive non-Hodgkin lymphoma (NHL)","volume":"130","author":"Locke","year":"2017","journal-title":"Blood"},{"issue":"2","key":"2024082712403397400_bib98","first-page":"S255","article-title":"Siltuximab prophylaxis prior to standard of care CD19 directed chimeric antigen receptor T-cell therapy for B-cell lymphomas: interim results from a phase I clinical trial, transplantation and cellular therapy","volume":"30","author":"Voorhess","year":"2024","journal-title":"Transplant Cell Ther"},{"issue":"suppl 1","key":"2024082712403397400_bib99","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1182\/blood-2022-169809","article-title":"Siltuximab for First-line treatment of cytokine release syndrome: a response to the national shortage of tocilizumab","volume":"140","author":"Patel","year":"2022","journal-title":"Blood"},{"issue":"1","key":"2024082712403397400_bib100","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40164-021-00209-2","article-title":"Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy","volume":"10","author":"Zhang","year":"2021","journal-title":"Exp Hematol Oncol"},{"issue":"suppl 1","key":"2024082712403397400_bib101","doi-asserted-by":"crossref","first-page":"10350","DOI":"10.1182\/blood-2022-169382","article-title":"JAK1 inhibition during CAR T-cell treatment does not affect CAR T-cell proliferation, persistence, or function","volume":"140","author":"Pratta","year":"2022","journal-title":"Blood"},{"issue":"22","key":"2024082712403397400_bib102","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1182\/blood.V128.22.5702.5702","article-title":"Posterior reversible encephalopathy syndrome (PRES) after infusion of anti-Bcma CAR T cells (CART-BCMA) for multiple myeloma: successful treatment with cyclophosphamide","volume":"128","author":"Garfall","year":"2016","journal-title":"Blood"},{"issue":"18","key":"2024082712403397400_bib103","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible apoptosis as a safety switch for adoptive cell therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"2024082712403397400_bib104","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1158\/1078-0432.CCR-18-1379","article-title":"Plasma exchange can be an alternative therapeutic modality for severe cytokine release syndrome after chimeric antigen receptor-T cell infusion: a case report","volume":"25","author":"Xiao","year":"2019","journal-title":"Clin Cancer Res"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4348\/2239697\/blooda_adv-2024-013044-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/16\/4348\/2239697\/blooda_adv-2024-013044-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,27]],"date-time":"2024-08-27T08:41:47Z","timestamp":1724748107000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/16\/4348\/516461\/CAR-T-cell-toxicities-from-bedside-to-bench-how"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,16]]},"references-count":104,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2024,8,27]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013044","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,16]]}}}